Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy

Immunotherapy ◽  
2017 ◽  
Vol 9 (10) ◽  
pp. 851-861 ◽  
Author(s):  
Minghui Zhang ◽  
Dr. Bin Zhang ◽  
Huirong Shi
Keyword(s):  
Ovarian Cancer ◽  
T Cells ◽  
Cancer Therapy ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Engineered T Cells

scholarly journals Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain

2017 ◽  
Vol 24 (1) ◽  
pp. 95-105 ◽  
Author(s):  
Saul J. Priceman ◽  
Dileshni Tilakawardane ◽  
Brook Jeang ◽  
Brenda Aguilar ◽  
John P. Murad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
Chimeric Antigen Receptor ◽  
Cancer Metastasis ◽  
Antigen Receptor ◽  
Breast Cancer Metastasis ◽  
Her2 Breast Cancer ◽  
Engineered T Cells ◽  
The Brain ◽  
Regional Delivery

scholarly journals The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies

2016 ◽  
Vol 22 (1) ◽  
pp. 27-33 ◽  
Author(s):  
Sarah J. Nagle ◽  
Alfred L. Garfall ◽  
Edward A. Stadtmauer
Keyword(s):  
T Cells ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Hematologic Malignancies ◽  
Engineered T Cells

scholarly journals Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2343-2354 ◽  
Author(s):  
Saar Gill ◽  
Sarah K. Tasian ◽  
Marco Ruella ◽  
Olga Shestova ◽  
Yong Li ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Myeloid Leukemia ◽  
Mouse Models ◽  
Chimeric Antigen Receptor ◽  
Myeloid Leukemia ◽  
Antigen Receptor ◽  
Key Points ◽  
Human Acute Myeloid Leukemia ◽  
Engineered T Cells ◽  
Acute Myeloid

Key Points Targeting of CD123 via CAR-engineered T cells results in rejection of human AML and myeloablation in mouse models.

Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer immunotherapy.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3022-3022
Author(s):  
Michel Sadelain ◽  
Maud Condomines ◽  
Zeguo Zhao ◽  
Renier J. Brentjens ◽  
Isabelle Riviere
Keyword(s):  
T Cells ◽  
Cancer Immunotherapy ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Engineered T Cells

scholarly journals ATIM-13. PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTOR-ENGINEERED T CELLS TARGETING IL13Rα2 FOR THE TREATMENT OF GLIOBLASTOMA

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi20-vi20 ◽  
Author(s):  
Christine Brown ◽  
Darya Alizadeh ◽  
Renate Starr ◽  
Lihong Weng ◽  
Jamie Wagner ◽  
...  
Keyword(s):  
T Cells ◽  
Phase I ◽  
Chimeric Antigen Receptor ◽  
Phase I Study ◽  
Antigen Receptor ◽  
Engineered T Cells

scholarly journals Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

2017 ◽  
Vol 25 (1) ◽  
pp. 259-273 ◽  
Author(s):  
Lynsey M. Whilding ◽  
Ana C. Parente-Pereira ◽  
Tomasz Zabinski ◽  
David M. Davies ◽  
Roseanna M.G. Petrovic ◽  
...  
Keyword(s):  
T Cells ◽  
Solid Tumors ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Integrin Expression ◽  
Engineered T Cells ◽  
Αvβ6 Integrin
Sign in / Sign up

Export Citation Format

Share Document